Powder: -20°C for 3 years | In solvent: -80°C for 1 year
EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-derived (prostacyclin) vasodilators.[1],[2]Cytochrome P450 (CYP450) metabolism of polyunsaturated fatty acids produces epoxides such as (±)14(15)-EET which are prime candidates for the actual active mediator.[3] However, the CYP450 metabolites of eicosapentaenoic acid and docosahexaenoic acid have been little studied relative to arachidonate epoxygenase metabolites. (±)16(17)-EpDPA is the DHA homolog of (±)14(15)-EpETrE, derived via epoxidation of the 16,17-double bond of DHA. The EDHF activity of (±)16(17)-EpDPA has not yet been determined. The epoxygenase metabolites of DHA have also been detected in a mouse inflammation model.[4]
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 μg | ¥ 498 | 待询 | ||
50 μg | ¥ 953 | 待询 | ||
100 μg | ¥ 1,798 | 待询 | ||
500 μg | ¥ 7,983 | 待询 | ||
1 mg | 待询 | 待询 |
产品描述 | EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-derived (prostacyclin) vasodilators.[1],[2]Cytochrome P450 (CYP450) metabolism of polyunsaturated fatty acids produces epoxides such as (±)14(15)-EET which are prime candidates for the actual active mediator.[3] However, the CYP450 metabolites of eicosapentaenoic acid and docosahexaenoic acid have been little studied relative to arachidonate epoxygenase metabolites. (±)16(17)-EpDPA is the DHA homolog of (±)14(15)-EpETrE, derived via epoxidation of the 16,17-double bond of DHA. The EDHF activity of (±)16(17)-EpDPA has not yet been determined. The epoxygenase metabolites of DHA have also been detected in a mouse inflammation model.[4] |
别名 | (±)16,17-EpDPE, (±)16,17 EDP, (±)16,17-epoxy Docosapentaenoic Acid, (±)16,17-epoxy DPA, (±)16(17)-EpDPA |
分子量 | 344.495 |
分子式 | C22H32O3 |
CAS No. | 155073-46-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL
DMF: 50 mg/mL
PBS (pH 7.2): 1 mg/mL
Ethanol: 50 mg/mL
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
(±)16(17)-EpDPA 155073-46-4 (±)16,17-EpDPE 16(17)-EpDPA (±)16,17 EDP 16,17 EDP (±)16,17-epoxy Docosapentaenoic Acid 16,17-epoxy Docosapentaenoic Acid (±)16(17) EpDPA 16,17-EpDPE (±)16(17)EpDPA 16,17-epoxy DPA (±)16,17-epoxy DPA Inhibitor inhibitor inhibit